How to Read an FDA Consent Decree

A consent decree reads like paperwork because most of it is boilerplate, but the moment a judge signs it, it stops being a negotiation and becomes a court order. Confusing the two — treating it as one more enforcement letter to file away — is the mistake that turns a bad year into a contempt proceeding.

In brief

A consent decree is a permanent injunction a company agrees to, entered in federal court under 21 U.S.C. § 332 — it settles a case the Department of Justice filed on FDA’s referral, rather than resolving it at trial.
Most decrees include language where the company neither admits nor denies the government’s allegations. Agreeing to the injunction’s terms is a separate thing from agreeing the underlying claims are true.
The decree usually binds more than the site named in the caption — individual corporate officers are often named personally, and what lifts the decree is meeting a defined standard, not waiting out a calendar term.
A decree is almost never the first document in the file. It sits at the end of a chain that usually runs through an inspection, a Form 483, and often an unresolved warning letter.

What a decree actually is

Section 302 of the FD&C Act, codified at 21 U.S.C. § 332, authorizes a federal court to enjoin violations of the Act — the same prohibited acts, like introducing an adulterated or misbranded product into interstate commerce, that 21 U.S.C. § 331 lists. When FDA refers a case for injunction, the Department of Justice files it in federal district court on the agency’s behalf. A consent decree is what happens when the named defendants agree to the injunction’s terms instead of litigating the case to a verdict — a negotiated settlement that still carries a judge’s signature and a court’s enforcement power behind it. That last part is the detail worth sitting with: once it’s entered, violating a consent decree isn’t a second warning letter. It’s contempt of court, and the penalties available to a judge for contempt are a different category of exposure than anything FDA can impose on its own.

What the terms are actually asking for

The specifics vary by case and by which FDA center is involved, so read the actual document rather than assuming a template — but a working set of elements recurs often enough to be worth knowing before you open one. Decrees commonly halt manufacturing or distribution of the named products until specific conditions are certified met; require a written remediation plan, often reviewed by an independent expert or auditor the company pays for; give FDA the right to unannounced inspections for a period after operations resume; and set escalating, pre-agreed penalties for any future violation, which is what makes a second slip so much more expensive than the first one was. Some decrees also require the company to disgorge profits earned during the period of violation. None of this makes the underlying obligations new — it’s usually the same CGMP or quality system requirements the company already had, now with a court, not just an agency, checking the work.

Reading a decree in order

What triggered it — the violations alleged in the complaint filed alongside the decree.
Who is bound — the corporate entity, and any individuals named personally.
What has to stop, and the conditions under which it can resume.
What lifts it — the standard the company has to meet, not a date on a calendar.

For anyone evaluating a company from outside — sizing up an employer, a supplier, or a partner — a decree still in effect is a more serious signal than an open warning letter, precisely because it means a court, not just FDA, is watching. But it’s also a snapshot: a company operating years into a decree with a clean unannounced-inspection record is a genuinely different story than one in its first six months, even though both show up the same way in a headline.

Where this goes wrong

Assuming a decree ends when the coverage does

Most decrees run until specific compliance milestones are certified, sometimes years out, with FDA oversight built in for a period even after the company resumes normal operations.

Reading “neither admit nor deny” as a win

That language avoids a formal factual finding, but it does nothing to soften the injunction’s terms — and it does nothing at all to soften what happens if the company violates them next.

A consent decree is administrative machinery, not a headline event on its own. What it actually does is take an obligation the company already had and make it enforceable by a court instead of only by an agency — which is exactly why the terms are worth reading closely rather than filing away.

Sources & further reading

Cornell Legal Information Institute — 21 U.S.C. § 332, Injunction Proceedings law.cornell.edu
Cornell Legal Information Institute — 21 U.S.C. § 331, Prohibited Acts law.cornell.edu
Regulatory Academy — How to Write a Response to an FDA Warning Letter regulatoryacademy.com
Regulatory Academy — How to Read an FDA Establishment Inspection Report regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.

How to read an FDA consent decree